

Pyrazine derivatives

R 0550

DOI: 10.1002/chin.201041163

41- 163

The Asymmetric Synthesis of Sitagliptin, a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. — Key step in the improved synthetic pathway to sitagliptin (VII), a new DPP-IV inhibitor for the treatment of type 2 diabetes mellitus, is an asymmetric Michael addition to give intermediate (IV). Overall yield for the 9-step strategy is $\approx 31\%$. — (LIU*, F.; YU, W.; OU, W.; WANG, X.; RUAN, L.; LI, Y.; PENG, X.; TAO, X.; PAN, X.; J. Chem. Res. 34 (2010) 4, 230-232, DOI:10.3184/030823410X12709912414009 ; Sch. Perfum Aroma Technol., Shanghai Inst. Technol., Shanghai 200235, Peop. Rep. China; Eng.) — H. Haber

